NDC product
Darifenacin
NDC 16571-767 · Rising Pharma Holdings, Inc.
Key facts
| Product NDC | 16571-767 |
|---|---|
| Proprietary name | Darifenacin |
| Nonproprietary name | Darifenacin |
| Substances | DARIFENACIN HYDROBROMIDE |
| Dosage form | TABLET, FILM COATED, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Rising Pharma Holdings, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA206743 |
| Pharmacologic classes | Cholinergic Muscarinic Antagonist [EPC], Cholinergic Muscarinic Antagonists [MoA] |
| Marketing start | Sep 19, 2016 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: